Revive Therapeutics Ltd (QB) (RVVTF) Quote

OMG .Oo7 how the long covid. The CEO needs to go to jail!!! Making false allegations about his product. Promises that never came true. Literally he should go to prison for financial fraud. Can't even hold a penny. MF I hope a bus comes by an pick you up. When we will get a new CEO. f joke. I hope he comes to Chicago we could show him the Chicago smile and the hospitality.

OMG .Oo7 how the long covid. The CEO needs to go to jail!!! Making false allegations about his product. Promises that never came true. Literally he should go to prison for financial fraud. Can't even hold a penny. MF I hope a bus comes by an pick you up. When we will get a new CEO. f joke. I hope he comes to Chicago we could show him the Chicago smile and the hospitality.

Nobody cares and not enough volume to cover the cost issue of the news.

NEWS: Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures

SEP 18, 2024


https://revivethera.com/2024/09/revive-therapeutics-announces-strategic-focus-on-bucillamine-for-infectious-diseases-and-medical-countermeasures/

It'll go back up, buy now if you want to make a little money.

Down down down

Omg.

Almost made back all the money I lost by working overtime, PB. I haven't sold a share but hope for a miracle. If I bought the same number of shares today, I'd own 50% of the company with MF.

ps. more delays. Didn't see that coming although I'm not sure we can blame the big guy for that one. Monkeypox- here we come.

Bucillamine showed promise, but MF is a con man. It's very sad to see that MF is taking advantage, he treats shareholders like ATMs to cover his personal expenses. I still see many loyal shareholders posting here. At this point, it's a choice between moving on or holding out for a miracle, which could still happen.

Bucillamine cures every Damn Thing

Is this the Real Deal.....this time?

Will Mr. Frank ever come through??

$RVVTF Breaking News! Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections https://finance.yahoo.com/news/revive-therapeutics-provides-research-study-110000328.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via
@YahooFinance

Yes your right as fck....lol

Ps. But bucillamine can work if the Ceo wasn't such a Dumb ass.....he just want his 30k salary what a piece of Chit yea fo Golfing fck investors his so Dumb .....

You and everyone else..MF stole all the money from the shareholders collecting a six figure salary and running this into the ground...only a miracle can get us out of this mess imo

You’re such a bag holder!!!!

Investing in Rvvtf is like drinking tequila and puking hard


MF is the biggest scam artist. If I could puke all over him right now I would

Investing in RVVTF and drinking go together like peanut butter and jelly. Good luck my man.

I muted the a hole lol..man really I shouldn't post here when drinking or not invested for now.. some of his post reply seem same as when Mf was a D ick replying to worried investors so maybe u right.. i. I wouldn't put it past Mf
Ps. Cw yes it sucks no vegas meet etc.. and what the fck they tell investors for 18 months we have possible Symptoms data when like the post last week I post....they should of known the trial didn't have Chit for Symptoms the Fda wanted because it was basic;
Ps. Still not giving up on getting money
Back I have a damn good chance wish all rvvtf investors get it back somehow
Pps. I still think bucillamine can still help with many infectious diseases

That's why I might buy back if the moons are align lol...

Dig back a year or more back and I said here that $RVVTF could and might go after this application, because Bucci had this potential based on what was already known, and what do you know, there it is.

Great post:



Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

July 02, 2024 13:58 ET

TORONTO, July 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. Control studies have been initiated and the DRDC expects to evaluate the data this month. Treatment studies will follow after the conclusion of the control group evaluation. The research study is expected to be completed in August 2024.

Nerve agents are chemicals that affect the nervous system. Nerve agents are highly toxic regardless of the route of exposure. The main chemical nerve agents that are man-made and manufactured for use in chemical warfare are sarin, soman, tabun and VX. These nerve agents are known to be present in military stockpiles. Exposure to nerve agents can occur due to chemical warfare or accidental release from a military storage facility. Exposure to nerve agents can cause tightness of the chest, excessive salivation, abdominal cramps, diarrhea, blurred vision, tremors, and death.

Recent studies have shown that antioxidant compounds such as n-acetylcysteine (“NAC”) could be beneficial in limiting seizure activity and improving the anticonvulsant efficacy of GABA-mediating drugs such as diazepam.

Bucillamine is a significantly more effective antioxidant than NAC and has the potential to provide increased efficacy against seizure activity while limiting the anticoagulant and bleeding event liability observed with NAC. The overall objective of the research project is to investigate pharmacological means for neuroprotection of GABA(A) receptors, which are required for the effectiveness of currently fielded anticonvulsant therapies. Bucillamine and NAC will be evaluated to determine the effect on GABA(A) receptor endocytosis and the effect on diazepam effectiveness in terminating seizures. Any additional antioxidant effects on seizure activity and survival will also be assessed.

The results from this research study, if promising, will determine further studies to facilitate FDA and Health Canada approvals for the use of Bucillamine in nerve agents or organophosphate pesticide poisoning. Also, the Company may explore the potential of Bucillamine for traumatic brain injury caused by concussive or explosive forces.

https://www.globenewswire.com/news-release/2024/07/02/2907735/0/en/Revive-Therapeutics-Provides-Update-on-Research-Study-Evaluating-Bucillamine-for-Nerve-Agent-Exposure.html

Gator Man! What's up. Now all we need is for rickthedickstereo to show up. Wish I had a dime for every lame "poor trial design" excuse from Loser investors. Hear it on damn near every failed trial. Denial is a defense mechanism.

Great article. https://www.safalniveshak.com/hope-is-not-an-investing-strategy/

“Any time you find yourself hoping in this business, the odds are that you are on the wrong path — or that you did something stupid that should be corrected." -Richard Russell, Dow Theory

Wait for me maybe buy back in lol....if things go OK with other stock always been bullish on Bucy but management lol...Ops
Not sure ...
Like this...That is BS. The FDA is a joke, but the reason Buci failed was because of a poor trial design which included the lack of tracking symptoms resolution. RVVTF and the trial designer’s are solely at fault. No doubt that Buci works; the ball was fumbled at the goal line.— Hattrick7 (@Hattrick710) May 8, 2024

Looking forward to positive and material news from management. GLTA shareholders

Keeping hope alive!

Nice reversal bounce today here on RVVTF , and no news I could see.

From a non newbie plenty of other baby bios with more impressive opportunities

All my opinion

$RVVTF Management team https://revivethera.com/management/

Newbie eyes here!!

Joker

$RVVTF Dip buy is a gift imo..

haha, funny. You're showing your age....

OMG under a penny. And today MF trying to pump it. Results will be end of the month on the BS testing on clinical trial. LoL . And headlight it's going to read. Recommendation to do some more testing blah blah blah. And it looks like no one cares.

You might want to go back to your room.

You might want to take your medicine again.

As I am heading out the door, I just found this chip under my chair.

Erratic behavior requires no information. Nice try.

aren't you clever. You have too much time on your hands. Key word in "on here!" Information has to come from many sources. So many posters on here have an agenda. You're one of them.

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

July 02, 2024 13:58 ET

TORONTO, July 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. Control studies have been initiated and the DRDC expects to evaluate the data this month. Treatment studies will follow after the conclusion of the control group evaluation. The research study is expected to be completed in August 2024.

Nerve agents are chemicals that affect the nervous system. Nerve agents are highly toxic regardless of the route of exposure. The main chemical nerve agents that are man-made and manufactured for use in chemical warfare are sarin, soman, tabun and VX. These nerve agents are known to be present in military stockpiles. Exposure to nerve agents can occur due to chemical warfare or accidental release from a military storage facility. Exposure to nerve agents can cause tightness of the chest, excessive salivation, abdominal cramps, diarrhea, blurred vision, tremors, and death.

Recent studies have shown that antioxidant compounds such as n-acetylcysteine (“NAC”) could be beneficial in limiting seizure activity and improving the anticonvulsant efficacy of GABA-mediating drugs such as diazepam.

Bucillamine is a significantly more effective antioxidant than NAC and has the potential to provide increased efficacy against seizure activity while limiting the anticoagulant and bleeding event liability observed with NAC. The overall objective of the research project is to investigate pharmacological means for neuroprotection of GABA(A) receptors, which are required for the effectiveness of currently fielded anticonvulsant therapies. Bucillamine and NAC will be evaluated to determine the effect on GABA(A) receptor endocytosis and the effect on diazepam effectiveness in terminating seizures. Any additional antioxidant effects on seizure activity and survival will also be assessed.

The results from this research study, if promising, will determine further studies to facilitate FDA and Health Canada approvals for the use of Bucillamine in nerve agents or organophosphate pesticide poisoning. Also, the Company may explore the potential of Bucillamine for traumatic brain injury caused by concussive or explosive forces.

https://www.globenewswire.com/news-release/2024/07/02/2907735/0/en/Revive-Therapeutics-Provides-Update-on-Research-Study-Evaluating-Bucillamine-for-Nerve-Agent-Exposure.html

This is what you said today, "...if you rely only on information on here to drive your investment process you won't be successful."
This is what you said last week, "I come to these boards for information..."

I'm just here for fun too. Does that make you simple minded?

You're very simple minded. I've neither pumped the stock or bashed it. I'm just here for fun, if you rely only on information on here to drive your investment process you won't be successful.

Wow under penny. MF need to go!! Where is Canada Gov for help.

And people who pump stocks don't have an ulterior motive?

that is semantics, we all judge others when they write, it's human nature.....I come to these boards for information not to read the same old thing over and over. Say it once and move on, no reason to beat a dead horse again and again. People that continue to bash stocks again and again obviously have an ulterior motive. MY OPINION!!!

With all due respect I do not see any judgement on this board...only opinion.

I agree.

For you to make a judgement about someone you don't know is par for the course.